Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropsacitinib (PF-06826647) in moderate to severe plaque psoriasis
NCT03895372Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of ropsacitinib in plaque psoriasis (5 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With a Psoriasis Area and Severity Index 90 Response at 16 weeks and Number of Participants With Treatment-Emergent Adverse Events at 40 weeks. Started Jun 2019; status: completed.
02
Drugs
ropsacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03895372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895372.